文献速递病毒性肝炎

乙型肝炎病毒感染的免疫发病机制

Immunopathogenesis of Hepatitis B Virus.
PubMed 文献 · J Infect Dis · 2017-01-01

HBV感染非细胞病变,肝损伤主要由宿主免疫应答介导,病毒在早期很少诱导I型干扰素反应。急性乙肝中先天免疫检测并抑制病毒,随后强适应性免疫应答伴病毒清除;慢性乙肝中先天和适应性免疫均弱,很少清除病毒。干扰素α和核苷(酸)类似物是获批抗病毒治疗,但单用或联合仍远未达到HBsAg血清清除,免疫治疗仍是最有希望的治愈方式。

要点

  • 肝损伤主要由宿主免疫应答介导,病毒本身非细胞病变
  • 急性乙肝免疫应答强可清除病毒,慢性乙肝免疫应答弱难以清除

核心结论

  • HBV感染非细胞病变,肝损伤主要由宿主免疫应答介导。
  • 急性乙肝中先天和适应性免疫应答强,常导致病毒清除;慢性乙肝中两者均弱,很少清除病毒。
  • 现有抗病毒治疗单用或联合仍远未达到HBsAg血清清除,免疫治疗是最有希望的治愈方式。

研究设计与样本

  • 本文为综述,总结HBV免疫发病机制及治疗相关免疫学基础。

主要发现

  • 围产期感染通常导致慢性乙肝,成年期感染多表现为急性乙肝并常清除病毒。
  • HBV感染早期很少诱导I型干扰素反应,呈“ stealthy”特性。
  • 急性乙肝中先天免疫检测并抑制病毒,随后强适应性免疫应答伴病毒清除。
  • 慢性乙肝中先天和适应性免疫应答均弱,很少导致病毒清除。

关键数值与推荐

  • 干扰素α治疗激活NK细胞和NKT细胞,部分增强先天免疫应答。
  • 核苷(酸)类似物通过抑制逆转录酶抑制病毒复制,可能恢复HBV特异性适应性免疫应答。
  • 单用或联合干扰素α与核苷(酸)类似物仍远未达到HBsAg血清清除。
  • 临床试验中多种免疫调节剂增强抗病毒免疫的治疗反应不理想。

临床怎么用

  • 理解HBV免疫发病机制有助于解释急性与慢性感染的不同结局。
  • 现有抗病毒治疗目标为抑制病毒复制,但难以实现HBsAg血清清除。
  • 免疫治疗是未来实现HBV治愈的最有希望方向。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic hepatitis B virus (HBV) infection is a global public health issue. There are >250 million people chronically infected with HBV, and these chronic carriers are at high risk of developing end-stage liver diseases and hepatocellular carcinoma. Patients with chronic hepatitis B (CHB) usually acquire the virus perinatally, while most patients infected during adulthood develop acute hepatitis B (AHB), which usually results in viral clearance. HBV infection is noncytopathic, and liver injury is mostly contributed by host immune responses. The virus is stealthy, since the infection rarely induces type I interferon response in the early phase. In AHB, viral infection is detected and restrained by the innate immune response, which is followed by a strong and robust adaptive immune response and accompanied by viral clearance. In patients with CHB, both innate and adaptive immune responses are weak and thus rarely lead to viral clearance. Interferon α and nucleos(t)ide analogues are 2 classes of approved antiviral therapies. The former treatment activates nature killer (NK) cells and NK T cells, which partially enhances the innate immune response, while the later treatment suppresses viral replication by inhibiting reverse transcriptase, which may restore the HBV-specific adaptive immune response. However, single or combined treatment are still far from achieving seroclearance of HBV surface antigen. Although the treatment response is unsatisfactory in current clinical trials using several immunomodulators for boosting antiviral immunity, immunotherapy that is able to induce immune surveillance is still the most promising modality for HBV cure in the future.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Tseng TC, Huang LR. Immunopathogenesis of Hepatitis B Virus. J Infect Dis. 2017. PMID: 29156047. doi:10.1093/infdis/jix356

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。